恩替卡韦联合自拟中药治疗代偿期乙型肝炎肝硬化患者对血清细胞因子水平的影响

doi:10.3969/j.issn.1672-5069.2017.06.033

Abstract

Li Hongzhe, Wu Jinhai. Efficacy of combination of entecavir and herbal medicine in the treatment of patients with compensated hepatitis B liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 762-763.

References

[1] 勾文忠. 拉米夫定结合补阳还五汤治疗乙型肝炎肝硬化代偿期55例临床观察. 中国民族民间医药,2015, 24（24）:95-96.
[2] 赵娟. 中西医结合治疗对慢性乙型肝炎肝郁脾虚型患者血清IL-18和IFN-γ的影响. 现代中西医结合杂志,2014,23（30）:3356-3357.
[3] 莫潘清,金胜,张鼎. 中西医结合治疗乙型肝炎后肝硬化对患者肝功能的影响. 黑龙江医学,2017,41（2）:133-134.
[4] 刘平,刘成,胡义扬,等. 扶正化瘀方治疗肝炎后肝硬化的临床观察. 中国中西医结合杂志,2010,16（8）:459-462.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志,2016,19（3）：Ⅴ-ⅩⅩⅢ.
[6] Mehmedovi A,Mesihovi R,Prnjavorac B,et al. Non-invasive liver fibrosis markers:use of serum levels of cytokines IL 1α and TGF β1 in management of chronic liver diseases. Med Glas （Zenica）,2013,10（1）:20-27.
[7] Gao S,Ji X,Li F,et al. Aberrant DNA methylation of G protein coupled bile acid receptor Gpbar1 predicts prognosis of acute on chronic hepatitis B liver failure. J Viral Hepat,2015,22（2）:112-119.
[8] Agrawal A,Samrat SK,Agrawal B,et al. Co-incubation with core proteins of HBV and HCV leads to modulation of human dendritic cells. Viral Immunol,2014,27（8）:412-417.
[9] Manea I,Manea CN,Miron N, et al. Immunological aspects in viral hepatitis B and C infection. Roum Arch Microbiol Immunol,2011,70（3）:97-100.
[10] 方雪晴,张骏飞,宋海燕,等. 间充质干细胞移植及其在失代偿期肝硬化中研究进展. 中华传染病杂志,2016,34（8）:509-512.
[11] 周诗君,叶英,李家斌. 脐血干细胞移植治疗失代偿期肝硬化的疗效及安全性评价. 安徽医科大学学报,2016,51（7）:1035-1038.
[12] 阎勤. 乙型肝炎解毒汤联合恩替卡韦治疗慢性乙型肝炎86例临床观察. 中医临床研究,2017,9（2）:42-43.
[13] 聂红明,叶青艳,陈逸云,等. 中医辨证联合抗病毒治疗对乙型肝炎肝硬化发生率的影响. 时珍国医国药,2016,27（2）:379-383.
[14] 代雪枫,齐晓林,马勇,等. 超声介入法治疗代偿期乙型肝炎肝硬化109例疗效分析. 实用肝脏病杂志,2015,18（4）:375-378.
[15] 程丹,刘佳,郝尧坤,等. 中西医结合治疗病毒性肝炎后肝硬化思路及用药特色. 广州中医药大学学报,2014,31（3）:459-463.
[16] 张德奎,冯彦虎,王祥,等. 中西医结合治疗肝炎后肝硬化腹水疗效观察. 西部中医药,2013,26（2）:91-92.
[17] 佟绍刚. 中西医结合治疗乙型肝炎后肝硬化的疗效观察.大家健康（下旬版）,2016,10（5）:114.

Efficacy of combination of entecavir and herbal medicine in the treatment of patients with compensated hepatitis B liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[7]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[11]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[12]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[13]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[14]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[15]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.